Lumida
/TRVI
⌘K
Trevi Therapeutics Inc

Trevi Therapeutics Inc

TRVI
$17.05USD+2.90%+0.48 today

MARKET CAP

2.4B

P/E (TTM)

FWD P/E

DAY RANGE

$16 – $17

52W RANGE

$7
$20

AI Summary

Stalk
StalkMedium

TRVI remains in a medium-term bullish advance with clear higher highs and higher lows since late May. Price has pulled back into the intermediate EMAs and near horizontal support, offering a deferred entry opportunity. Short-term conditions are neutral without signs of exhaustion, so patience is warranted until acceptance at the EMAs. The long-term trend stays intact above major moving averages, while the key risk is a break below the 50 SMA and support area that would invalidate the bullish bias.

  • Phase IIa River Trial delivered 57% placebo-adjusted cough reduction (p<0.0001).
  • Maintained $172M cash at Q1 2026, funding trials through 2030.
  • Reported Q1 2026 net loss of $11.8M, reflecting steep cash burn.
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICTREND
Sales, Adj.
YoY %
P / Sales
EV / Sales
Gross Profit, Adj.
YoY %
Margin %
EV / Gross Profit
EBITDA, Adj.
YoY %
Margin %
EV / EBITDA
EBIT
YoY %
Margin %
EV / EBIT
Net Income
YoY %
Net Margin
EPS (GAAP)
YoY %